Physician profile
Imran Junaid
NPI 1285801787
$34,952.70
in general payments reported to CMS, 2019-2025
50 companies · $4,618 in 2025
The $4,618 reported for 2025 was more than what 85% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,057 · 2020: $958 · 2021: $2,363 · 2022: $12K · 2023: $9,378 · 2024: $2,671 · 2025: $4,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,006 · Travel and Lodging: $136 · Education: $17.71 · Consulting Fee: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,500.00 |
| Food and Beverage | $5,006.44 |
| Travel and Lodging | $135.50 |
| Education | $17.71 |
| Consulting Fee | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20,402.99 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $5,397.52 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,997.61 | 2019-2025 | |
| Amgen INC. | $1,819.75 | 2019-2025 | Tezspire, Prolia, Evenity |
| Regeneron Healthcare Solutions, INC. | $795.57 | 2019-2024 | Dupixent |
| Inspire Medical Systems, INC. | $624.63 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.11 | 2019-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $263.45 | 2019-2022 | |
| Novo Nordisk INC | $252.40 | 2019-2025 | Wegovy |
| Resmed Corp | $226.65 | 2023-2025 | |
| Mannkind Corporation | $214.00 | 2019-2023 | Afrezza |
| Lilly USA, LLC | $178.67 | 2019-2022 | |
| Genentech USA, INC. | $177.90 | 2020-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $171.11 | 2019-2025 | |
| Optinose US, INC. | $139.91 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Junaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.